Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms KINECT-2
  • Sponsors Neurocrine Biosciences

    • Most Recent Events

    • 01 Mar 2019 Results of a pooled analysis assessing the effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder in KINECT 2, KINECT 3 and KINECT 3 extension studies, published in the Journal of Affective Disorders
    • 16 Jan 2019 Results of a pooled post-hoc analysis from KINECT 2, KINECT 3 and KINECT 3 extension studies published in a Neurocrine Biosciences Media Release.
    • 27 Apr 2018 Results of a pooled analysis from KINECT, KINECT 2, and KINECT 3 studies assessing minimal clinically important difference (MCID) for Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score in tardive dyskinesia, presented at the 70th Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top